Asco-GU 2019 – checkpoint blockers might not be created equal after all
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Merck’s Keytruda Fails in Late-Stage HCC Trial
Merck’s Keytruda Fails in Late-Stage HCC Trial
Marketing Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Marketing
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Keytruda Combination Set to Become a Cornerstone Therapy in Renal Cell Carcinoma
Keytruda Combination Set to Become a Cornerstone Therapy in Renal Cell Carcinoma
Novartis’ Busy Day: 10-Target Deal With AbCellera and FDA Approves Parasite Drug
Novartis’ Busy Day: 10-Target Deal With AbCellera and FDA Approves Parasite Drug
Merck Eyes Plans Phase III Programs in Prostate Cancer With Keytruda
Merck Eyes Plans Phase III Programs in Prostate Cancer With Keytruda
Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
ASCO GU Preview: Merck, Bristol-Myers Squibb, Pfizer and More
ASCO GU Preview: Merck, Bristol-Myers Squibb, Pfizer and More
Glaxo adds flesh to its oncology ambitions
Glaxo adds flesh to its oncology ambitions
Upcoming events – Cancer readouts for Merck & Co and Seattle
Upcoming events – Cancer readouts for Merck & Co and Seattle
GSK-MERCK: Συνεργάζονται για μια νέα ανοσοθεραπεία κατά του καρκίνου
GSK-MERCK: Συνεργάζονται για μια νέα ανοσοθεραπεία κατά του καρκίνου
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
FDA Action Alert: Sanofi, Motif Bio and Merck
FDA Action Alert: Sanofi, Motif Bio and Merck
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns Over Drug Pricing
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s … Continue Reading Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns Over Drug Pricing
10 Takeover Targets to Watch in 2019
0 Takeover Targets to Watch in 2019
The 2019 pipeline report: Changing the treatment paradigm
The 2019 pipeline report: Changing the treatment paradigm
